Drug
Bnt162b2
Bnt162b2: highest development phase Phase 3, developed by BioNTech. 6 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- BioNTech
Trials
| Drug | Phase | Indication |
|---|---|---|
| BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) NCT07069309 | Phase 3 | COVID-19 |
| BNT162b2 NCT04713553 | Phase 3 | SARS-CoV-2 Infection |
| BNT162b2 (Omi XBB.1.5) NCT05997290 | Phase 2/3 | SARS-CoV-2 Infection |
| BNT162b2 NCT04895982 | Phase 2 | SARS-CoV-2 Infection, COVID19 |
| BNT162b2 NCT04649021 | Phase 2 | SARS-CoV-2 |
| BNT162b2 NCT05004181 | Phase 2 | SARS-CoV-2 Infection |
Latest
No recent events.
Follow Bnt162b2 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.